What is William Blair's Estimate for APLT Q3 Earnings?

Key Points

• William Blair has raised its Q3 2025 earnings per share (EPS) estimate for Applied Therapeutics Inc. to ($0.15), up from the previous estimate of ($0.16).
• The current consensus estimate for Applied Therapeutics' full-year earnings stands at ($0.65) per share, with projections indicating EPS will remain negative in subsequent quarters.
• Institutional investors hold a significant stake in Applied Therapeutics, with approximately 98.31% of the company’s stock owned by these investors.

Applied Therapeutics Inc. (NASDAQ:APLT - Free Report) - William Blair lifted their Q3 2025 earnings per share (EPS) estimates for Applied Therapeutics in a research report issued on Thursday, August 14th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($0.15) for the quarter, up from their prior forecast of ($0.16). The consensus estimate for Applied Therapeutics' current full-year earnings is ($0.65) per share. William Blair also issued estimates for Applied Therapeutics' Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.61) EPS, Q1 2026 earnings at ($0.16) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.63) EPS.

Other analysts have also recently issued reports about the company. Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a $1.50 price objective on shares of Applied Therapeutics in a research report on Wednesday, May 14th. Wall Street Zen upgraded Applied Therapeutics to a "sell" rating in a research note on Saturday, July 26th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, Applied Therapeutics currently has a consensus rating of "Hold" and a consensus price target of $6.10.

Applied Therapeutics Stock Up 1.5%

APLT opened at $0.48 on Monday. Applied Therapeutics has a 12-month low of $0.30 and a 12-month high of $10.62. The stock has a market cap of $69.00 million, a price-to-earnings ratio of -1.06 and a beta of 1.97. The business has a 50 day moving average of $0.41 and a 200-day moving average of $0.44.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.02.

Hedge Funds Weigh In On Applied Therapeutics

A number of large investors have recently made changes to their positions in the company. Birchview Capital LP bought a new position in shares of Applied Therapeutics during the second quarter worth approximately $87,000. Marshall Wace LLP increased its stake in Applied Therapeutics by 18.1% during the 2nd quarter. Marshall Wace LLP now owns 1,544,191 shares of the company's stock worth $479,000 after acquiring an additional 236,810 shares during the period. CreativeOne Wealth LLC increased its stake in Applied Therapeutics by 106.7% during the 2nd quarter. CreativeOne Wealth LLC now owns 104,213 shares of the company's stock worth $32,000 after acquiring an additional 53,800 shares during the period. AQR Capital Management LLC bought a new position in Applied Therapeutics during the 1st quarter worth $280,000. Finally, Alyeska Investment Group L.P. increased its stake in Applied Therapeutics by 14.8% during the 1st quarter. Alyeska Investment Group L.P. now owns 3,107,497 shares of the company's stock worth $1,519,000 after acquiring an additional 400,000 shares during the period. Institutional investors own 98.31% of the company's stock.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.